Nathan Connell: $50 Million Gift to Advance Cell and Gene Therapy at Mass General Brigham
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on LinkedIn:
“Transformational philanthropy is essential to advancing the next era of cellular and gene therapy.
The recently announced $50 million anonymous gift to support cancer research and cell and gene therapy across Mass General Brigham will help strengthen the infrastructure and translational science required to bring these therapies from discovery to patients.
In hematology, we are already beginning to see this shift in real time.
At Brigham and Women’s Hospital, our hemophilia program treated the first patient in New England with gene therapy for hemophilia B last year—a one-time infusion designed to enable the liver to produce factor IX, potentially replacing lifelong prophylactic factor therapy.
For patients who have spent decades managing a chronic bleeding disorder, the possibility that a single treatment could durably restore hemostasis represents a fundamental change in how we think about treatment.
Continued investment in academic gene therapy programs will be critical to expanding access, refining these approaches, and bringing the next generation of therapies to patients.
I am grateful to the visionary donors who are helping to accelerate our work.”
Stay updated with Hemostasis Today.
-
Mar 17, 2026, 15:28Aafreen Kotadiya: Why a Great Blood Bank Team is a Rare and Powerful Asset in Transfusion Medicine
-
Mar 17, 2026, 15:10Peter Zdziarski: Standing Together for Ultra Rare Bleeding Disorders Awareness Day
-
Mar 17, 2026, 14:58Heghine Khachatryan: PFO, Cryptogenic Stroke, and Factor V Leiden – Closure or Lifelong Anticoagulation?
-
Mar 17, 2026, 14:56Mahesan Subramaniam: A Visual Guide to Heart Valve Disease
-
Mar 17, 2026, 14:55Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
-
Mar 17, 2026, 14:52Kanishk Kumar: ATTR Amyloidosis Therapeutics Market Poised for a Pipeline Revolution
-
Mar 17, 2026, 14:39Giordano Botta: VA and Allelica Partner on Clinical Study of PRS and PGx in Cardiovascular Prevention
-
Mar 17, 2026, 14:34Rishi Wadhera: Financial Burden Among Working-Age Adults With Cardiovascular Disease
-
Mar 17, 2026, 14:32Kunal Mahajan: Lipoprotein(a) and LDL-C Target Attainment in ACS Patients